| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
20-Hydroxyganoderic Acid G was reported to inhibit LPS-induced NO production in microglia.[1]
|
|---|---|
| ln Vitro |
1. NO production inhibitory activity in LPS-induced BV-2 microglia: 20-Hydroxyganoderic Acid G (1 μM, 5 μM, 10 μM) was pretreated for 1 hour, then cells were stimulated with LPS (1 μg/mL) for 24 hours. It inhibited NO production in a concentration-dependent manner, with inhibition rates of (18.2 ± 2.3)% (1 μM), (45.6 ± 3.1)% (5 μM), and (68.9 ± 4.2)% (10 μM). The positive control (aminoguanidine, 100 μM) had an inhibition rate of (75.3 ± 3.8)% [1]
2. Cytotoxicity in BV-2 microglia: After 25 hours of treatment (1 hour pretreatment + 24 hours LPS stimulation) with 20-Hydroxyganoderic Acid G (1 μM, 5 μM, 10 μM), cell viability was > 90% (MTT assay) [1] |
| Cell Assay |
1. BV-2 microglia culture and NO detection assay:
a. Cells were cultured in DMEM (10% fetal bovine serum, 1% penicillin-streptomycin) at 37°C, 5% CO₂, seeded in 96-well plates (5×10⁴ cells/well) and adhered for 24 hours [1] b. 20-Hydroxyganoderic Acid G (1 μM, 5 μM, 10 μM, DMSO ≤ 0.1%) was pretreated for 1 hour, then LPS (1 μg/mL) was added. Medium-only and LPS-only groups were set as controls [1] c. After 24 hours, 50 μL supernatant mixed with 50 μL Griess reagent was incubated for 10 minutes, and absorbance was measured at 540 nm to calculate NO concentration [1] 2. MTT cell viability assay: a. After 25 hours of treatment, 20 μL MTT (5 mg/mL in PBS) was added and incubated for 4 hours at 37°C [1] b. Supernatant was removed, 150 μL DMSO was added to dissolve crystals, and absorbance was measured at 570 nm to calculate viability [1] |
| Toxicity/Toxicokinetics |
20-hydroxyganoderic acid G (1 μM, 5 μM, 10 μM) showed no significant cytotoxicity to BV-2 microglia, with cell viability >90% [1]
|
| References | |
| Additional Infomation |
According to reports, Ganoderma lucidum contains (6S)-6-hydroxy-2-methyl-4-oxo-6-[(3S,7S,10S,12S,13R,14R,17S)-3,7,12-trihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthrene-17-yl]heptanoic acid, and related data have been published. 1. 20-hydroxyganoderic acid G is a lanostane-type triterpenoid compound isolated from the fruiting body of Ganoderma lucidum[1]. 2. It may exert its anti-inflammatory effect by inhibiting the production of NO in activated microglia[1].
|
| Molecular Formula |
C30H44O9
|
|---|---|
| Molecular Weight |
548.6650
|
| Exact Mass |
548.298
|
| CAS # |
400604-12-8
|
| PubChem CID |
134715238
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.31±0.1 g/cm3(Predicted)
|
| Boiling Point |
760.1±60.0 °C(Predicted)
|
| LogP |
0.4
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
39
|
| Complexity |
1160
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O[C@@H]1C(C2=C([C@H](CC3C(C)(C)[C@H](CC[C@@]32C)O)O)[C@]2(C)C(C[C@]([H])([C@](C)(CC(CC(C(=O)O)C)=O)O)[C@]21C)=O)=O
|
| InChi Key |
HHCQRNABFNZPFW-BETRBYGXSA-N
|
| InChi Code |
InChI=1S/C30H44O9/c1-14(25(37)38)10-15(31)13-28(5,39)18-12-20(34)30(7)21-16(32)11-17-26(2,3)19(33)8-9-27(17,4)22(21)23(35)24(36)29(18,30)6/h14,16-19,24,32-33,36,39H,8-13H2,1-7H3,(H,37,38)/t14?,16-,17-,18+,19-,24+,27-,28-,29-,30-/m0/s1
|
| Chemical Name |
(6S)-6-hydroxy-2-methyl-4-oxo-6-[(3S,5R,7S,10S,12S,13R,14R,17S)-3,7,12-trihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]heptanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8226 mL | 9.1129 mL | 18.2259 mL | |
| 5 mM | 0.3645 mL | 1.8226 mL | 3.6452 mL | |
| 10 mM | 0.1823 mL | 0.9113 mL | 1.8226 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
